Every year, Polish news magazine Wprost publishes its ranking of the top 200 Polish companies across all industries. Here, we profile the top five pharma-related companies featured in the 2019 rankings.
NEUCA has been around for over 25 years and is active in numerous areas of the Polish healthcare market. The company is a leader in the wholesale distribution of pharmaceuticals – the core of its business activity – but also maintains a strong position in wholesale trade, pharmaceutical production, marketing, logistics, outpatient clinics network development, clinical trials, telemedicine, IT, advertisement and media.
NEUCA brands itself as an innovative company, conducting a number of start-up projects and introducing new solutions onto the healthcare market. The company has been listed on the WSE in Warsaw since 2004.
Founded in 1990, Farmacol is a pharmaceutical and medical product wholesaler. Since June 1999, the company’s shares have been listed on the Warsaw Stock Exchange. The company purchased shares in the Cefarm group companies, and is currently the majority shareholder in Cefarmy Kielce, Szczecin, Warsaw and Wrocław, with which it forms a capital group.
Farmacol has eight distribution centres in Katowice, Białystok, Gdańsk, Poznań, Rzeszów, Szczecin, Warsaw and Wrocław.
Polska Grupa Farmaceutyczna
Polska Grupa Farmaceutyczna brands itself as one of Poland’s largest and most modern drug distribution companies. Founded in 1990, the company works with over 600 pharmaceutical producers, providing access to a very wide range of products via its 13 distribution centres throughout Poland. The group has a 20 percent share of the domestic pharmaceutical distribution market
Polpharma is the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. The company actively operates in the markets of Central and Eastern Europe, the Caucasus and Central Asia.
Back in 2018, PharmaBoardroom spoke to Polpharma CEO Markus Sieger, who outlined the company’s strategic plan, mainly based on growth from new product launches and increasing sales on the existing portfolio.
“The company is driven by our three core markets but also by other countries, mostly in the CEE and CIS region, such as Hungary, Czech Republic, Uzbekistan, Ukraine and Vietnam,” he said. “Additionally, we are strongly developing our business to business activity (b2b), structured around three key segments: API supply, as Polpharma has a state-of-the-art API manufacturing plant in Poland, contract manufacturing operations and the out-licencing of our products.”
“Our strong position on the market allows us to be pioneers in technological change, so we can not only adapt to external factors but also shape the direction of the development of pharma market. This comes under the themes of digitisation and it allows Polpharma to be agile and efficient meeting expectations of patients, other key stakeholders and wholesalers. We aim to be digital marketing leader in communication with commercial partners and be able to effectively reach our OTC and CHC clients.”
Founded in 1951 and a public company since 1991, TZMO brands itself as a leading European manufacturer and supplier of sanitary articles, cosmetics and medical devices to the world market. By 2013, the firm had 54 companies in 17 countries with 7,300 employees. TZMO products are available on the market in 65 markets across Europe, Asia, Africa, America and Australia.